TITLE

Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom?

AUTHOR(S)
Orvieto, Raoul
PUB. DATE
August 2015
SOURCE
Journal of Ovarian Research;Aug2015, Vol. 8 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Controlled ovarian hyperstimulation (COH) which combines GnRH antagonist co-treatment and GnRH-agonist (GnRHa) trigger has become a common tool aiming to eliminate severe early OHSS and to support the concept of an OHSS-free clinic. However, due to the reported significantly reduced clinical, efforts have been made to improve reproductive outcome. One of the suggested optional strategies aiming to improve outcome was the addition of low-dose (1500 IU) HCG bolus, administered, concomitant, 35 h or 5 days after the triggering bolus of GnRHa. All these regimens were demonstrated to rescue the luteal phase, resulting in improved reproductive outcome in patients at risk to develop severe OHSS, compared to GnRHa trigger alone, however, with the questionable ability to eliminate severe OHSS. Moreover, following the observations demonstrating comparable or even better oocyte\embryos quality following GnRHa, compared to hCG trigger, and the different effects of LH and hCG on the downstream signaling of the LH receptor, GnRHa is now offered concomitant to the standard hCG trigger dose to improve oocyte/embryo yield and quality. GnRHa and hCG may be offered either concomitantly, 35-37 h prior to oocyte retrieval (dual trigger), or 40 h and 34 h prior to oocyte retrieval, respectively (double trigger).
ACCESSION #
109265583

 

Related Articles

  • Effects and Optimal Timing of HCG Supplementation of GnRHa.  // Fertility Weekly;12/18/2006, p4 

    The article cites a study conducted by researchers from Denmark which determined the effects of human chorionic gonadotropin (HCG) supplementation and optimal timing of HCG administration in vitro fertilization/intracytoplasmic sperm injection patients. The researchers have revealed that...

  • Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. Humaidan, P.; Kol, S.; Benadiva, C.; Engmann, L.; Papanikolaou, E.G. // Human Reproduction Update;Mar2012, Vol. 18 Issue 2, p229 

    No abstract available.

  • HCG: Is it the Best Choice for Ovulation Triggering? Humaidan, Peter; Bodri, Daniel; Papanikolaou, Evangelos G.; Kol, Shahar // Open Reproductive Science Journal;2012, Vol. 4, p1 

    With the increasing use of gonadotropin releasing hormone antagonist protocols, it has become an option to trigger ovulation with gonadotropin releasing hormone agonist which has several advantages over human chorionic gonadotropin triggering; among those an elimination or reduction in ovarian...

  • GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Humaidan, P.; Kol, S.; Papanikolaou, EG. // Human Reproduction Update;Jul2011, Vol. 17 Issue 4, p510 

    BACKGROUND GnRH agonist (GnRHa) triggering has been shown to significantly reduce the occurrence of ovarian hyperstimulation syndrome (OHSS) compared with hCG triggering; however, initially a poor reproductive outcome was reported after GnRHa triggering, due to an apparently uncorrectable luteal...

  • GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. Kolibianakis, E.M.; Griesinger, G.; Venetis, C.A. // Human Reproduction Update;Mar2012, Vol. 18 Issue 2, p228 

    No abstract available.

  • Low-Dose Human Chorionic Gonadotropin Adjunct to an Antagonist Protocol in Assisted Reproductive Technology: a Randomized Trial Study. Aghahosseini, Marzieh; Aleyasin, Ashraf; Yekehtaz, Habibeh; Kashani, Ladan // Acta Medica Iranica;2014, Vol. 52 Issue 6, p430 

    The aim of this study was to evaluate the outcomes of adding low-dose hCG (human chorionic gonadotropin), as an LH active supplement, to a GnRH antagonist protocol in patients undergoing assisted reproduction techniques. In this parallel-group randomized clinical trial, 137 infertile female...

  • GnRHa to trigger final oocyte maturation: a time to reconsider. Humaidan, P.; Papanikolaou, E. G.; Tarlatzis, B. C. // Human Reproduction;Oct2009, Vol. 24 Issue 10, p2389 

    Recently GnRH antagonist protocols for the prevention of a premature LH surge were introduced, allowing final oocyte maturation to be triggered with a single bolus of a GnRH agonist (GnRHa). GnRHa is as effective as hCG for the induction of ovulation, and apart from the LH surge a FSH surge is...

  • GnRHa for Final Oocyte Maturation Prior to Cryopreservation is Effective. Griesinger, G. // Fertility Weekly;5/14/2007, p8 

    The article reports on the study conducted by researchers in Germany which reveals that the use of gonadotropin-releasing hormone agonist (GnRHa) for final oocyte maturation prior to cryopreservation effectively reduces the risk of ovarian hyperstimulation syndrome (OHSS) and offers a chance of...

  • Benefits of luteinizing hormone activity in ovarian stimulation for IVF. Venetis, C. A; Kolibianakis, E. M.; Tarlatzi, T. B.; Tarlatzis, B. C. // Reproductive BioMedicine Online (Reproductive Healthcare Limited;2009 Supplement 2, Vol. 18 Issue S2, pS31 

    Knowledge of the physiology of folliculogenesis has led to a better understanding of the role of LH activity in this process. This role has been investigated in the setting of ovarian stimulation and several treatment modalities have been proposed. LH activity can be provided in the forms of:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics